Research Topics
| Robert L GiuntoliSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survivalRobert L Giuntoli
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Int J Gynecol Cancer 22:273-9. 2012..The aim of this study was to determine if comprehensive surgical staging is a better predictor of outcome than incomplete staging for women with stage I noninvasive or minimally invasive (≤3 mm) uterine serous carcinoma (USC)...
Secondary cytoreduction in the management of recurrent uterine leiomyosarcomaRobert L Giuntoli
The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, Maryland 21287, USA
Gynecol Oncol 106:82-8. 2007..To identify effective treatment options for patients with recurrent uterine leiomyosarcoma (LMS)...- Evaluation and management of adnexal masses during pregnancyRobert L Giuntoli
Hopkins Medical Institutions, Phipps 281, Baltimore, Maryland 21287, USA
Clin Obstet Gynecol 49:492-505. 2006..In the approximately 5% of cases in which an adnexal masses proves to be a malignancy, appropriate staging may be safely performed. In selected cases, chemotherapy should at least be entertained... - Uterine leiomyosarcoma: present managementRobert L Giuntoli
The Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Curr Opin Oncol 16:324-7. 2004..To review current investigations impacting management of uterine leiomyosarcoma (LMS)... - Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunityRobert L Giuntoli
The Kelly Gynecologic Oncology Service, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, Maryland 21287, USA
Anticancer Res 29:2875-84. 2009..To identify immunosuppressive elements present in ovarian cancer associated ascites... - Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysisRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Gynecol Oncol 106:476-81. 2007..To evaluate the cost-effectiveness of intraperitoneal cisplatin and paclitaxel chemotherapy as front-line treatment for patients with Stage III epithelial ovarian cancer following optimal primary cytoreductive surgery... - Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcomeRitu Salani
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Cancer 109:685-91. 2007.... - Secondary cytoreductive surgery including rectosigmoid colectomy for recurrent ovarian cancer: operative technique and clinical outcomeRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, MD 21287, USA
Gynecol Oncol 114:173-7. 2009..To describe the operative technique and associated clinical outcomes of patients undergoing rectosigmoid colectomy as a component of secondary cytoreductive surgery for recurrent ovarian cancer... - A clinical pathway for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for advanced ovarian and primary peritoneal cancersMelissa A Gerardi
The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Gynecol Oncol 108:282-6. 2008.... - Analysis of contemporary trends in access to high-volume ovarian cancer surgical careRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Ann Surg Oncol 16:3422-30. 2009..However, contemporary patterns of primary surgical care for ovarian cancer according to hospital and surgeon case volume remain poorly defined... - Impact of surgeon and hospital ovarian cancer surgical case volume on in-hospital mortality and related short-term outcomesRobert E Bristow
The Kelly Gynecologic Oncology Service, Departments of Gynecology and Obstetrics and Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
Gynecol Oncol 115:334-8. 2009..To evaluate the impact of surgeon and hospital case volume, and other related variables, on short-term outcomes after surgery for ovarian cancer... - Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinomaRitu Salani
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 600 N Wolfe St Phipps 281, Baltimore, Maryland 21224, USA
Ann Surg Oncol 14:3552-7. 2007.... - Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysisRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Cancer 109:1513-22. 2007..The objective of this study was to evaluate the cost-effectiveness of centralized referral of patients with advanced-stage epithelial ovarian cancer who underwent primary cytoreductive surgery and adjuvant chemotherapy... - Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillanceRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Gynecol Oncol 103:709-13. 2006..To examine the cost-effectiveness of routine vaginal cytology in detecting asymptomatic isolated vaginal recurrence during post-treatment endometrial cancer surveillance... - Salvage cytoreductive surgery for recurrent endometrial cancerRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
Gynecol Oncol 103:281-7. 2006..To determine the survival impact of salvage cytoreductive surgery, and other prognostic variables, among patients with recurrent endometrial cancer... 
Ascites specific inhibition of CD1d-mediated activation of natural killer T cellsTonya J Webb
Department of Pathology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA
Clin Cancer Res 14:7652-8. 2008..Given that ovarian cancer-associated ascites has been reported to have increased levels of gangliosides, we examined the effect of tumor-associated and other ascites on CD1d-mediated antigen presentation to NKT cells...- Concentration of uterine cancer surgical care among the elderly: a population-based perspectiveTeresa P Diaz-Montes
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Gynecol Oncol 107:436-40. 2007..To characterize the primary surgical care and short-term outcomes for uterine cancer in women age > or = 80 years compared to younger women... - Transverse colectomy in ovarian cancer surgical cytoreduction: operative technique and clinical outcomeRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, 600 NorthWolfe Street, Phipps 281, Baltimore, Maryland 21287, USA
Gynecol Oncol 109:364-9. 2008..To describe the operative techniques and associated clinical outcomes of patients undergoing transverse colectomy as a component of cytoreductive surgery for advanced or recurrent ovarian cancer... - Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancerShazia Bashir
The Kelly Gynecology and Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Gynecol Oncol 119:255-8. 2010..To describe the technique and short-term post-operative outcomes associated with diaphragm full-thickness resection (FTR) and intraoperative trans-diaphragmatic decompression of the resultant pneumothorax (TDDP)... - Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal rangeAntonio Santillan
Kelly Gynecology Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD, USA
J Clin Oncol 23:9338-43. 2005..To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum cancer antigen 125 (CA-125) levels that remain below the upper limit of normal (< 35 U/mL)... - Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93Stefanie M Ueda
Kelly Gynecologic Oncology Service, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Am J Pathol 175:2618-24. 2009..FASN inhibitors such as C93 warrant further investigation as targeted therapeutic agents for metastatic and chemoresistant gestational trophoblastic neoplasia... - Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancerTonya J Webb
Department of Pathology and The Kelly Gynecologic Oncology Service, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21201, USA
Cancer Res 72:3744-52. 2012..These data therefore indicate that ovarian cancer tumors may use GD3 to inhibit the antitumor NKT cell response as an early mechanism of tumor immune evasion... - The role of cytoreductive surgery for colon cancer metastatic to the ovaryColleen C McCormick
Department of Gynecology and Obstetrics, Kelly Gynecologic Oncology Service, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
Gynecol Oncol 105:791-5. 2007..We sought to further elucidate the survival impact of cytoreductive surgery among patients with colon cancer metastatic to the ovary... - Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control studyRitu Salani
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA
Gynecol Oncol 107:495-9. 2007..To evaluate clinicopathological factors and survival outcome of patients with advanced epithelial ovarian carcinoma undergoing multiple bowel resections to achieve optimal (< or = 1 cm) cytoreduction... - Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysisRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Obstetrics and Gynecology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Gynecol Oncol 104:739-46. 2007.... - Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortalityTeresa P Diaz-Montes
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
Gynecol Oncol 103:1043-7. 2006..To characterize the patterns of primary surgical care and short term outcomes for uterine cancer according to surgeon and hospital case volume... - Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behaviorRobert L Giuntoli
Kelly Gynecologic Oncology Service, Johns Hopkins University, Baltimore, Maryland, USA
J Reprod Med 52:1001-10. 2007..To determine the prognostic accuracy of current diagnostic criteria for uterine smooth muscle tumors... - Feasibility and economic impact of a clinical pathway for pap test utilization in Gynecologic Oncology practiceAntonio Santillan
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Gynecol Oncol 109:388-93. 2008..S. healthcare system of implementing a clinical pathway for Pap test utilization in screening and surveillance of gynecologic cancers in a university-based gynecologic oncology practice... - Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot studyJoyce N Barlin
Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, MD, USA
Clin Imaging 34:191-5. 2010..The objective of this study was to utilize computed tomographic peritoneography (CTP) to assess distribution prior to intraperitoneal chemotherapy for advanced müllerian cancer... - Evolution of a trophoblastic tumor from an endometrioid carcinoma--a morphological and molecular analysisMathew T Olson
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
Int J Gynecol Pathol 30:117-20. 2011.... - Surgical care of elderly women with ovarian cancer: a population-based perspectiveTeresa P Diaz-Montes
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Gynecol Oncol 99:352-7. 2005..To characterize the primary surgical care and short-term outcomes for ovarian cancer in women aged 80 years and older compared to women younger than 80 years... - Comparison of candidate serologic markers for type I and type II ovarian cancerDan Lu
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Gynecol Oncol 122:560-6. 2011..To examine the value of individual and combinations of ovarian cancer associated blood biomarkers for the discrimination between plasma of patients with type I or II ovarian cancer and disease-free volunteers... - Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodesRobert E Bristow
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
Gynecol Oncol 99:294-300. 2005..To evaluate the utility of combined positron emission tomography/computed tomography (PET/CT) for detecting recurrent epithelial ovarian cancer limited to retroperitoneal adenopathy... - Identification and characterization of a spontaneous ovarian carcinoma in Lewis ratsAllison C Sharrow
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Ovarian Res 3:9. 2010..Limited progress has been made toward improving the survival rate of patients with this disease in part because of the lack of a good animal model. We present here a model of spontaneous ovarian carcinoma arising in a normal Lewis rat... - Artificial antigen-presenting cells: artificial solutions for real diseasesMathias Oelke
Department of Pathology and Medicine, The Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
Trends Mol Med 11:412-20. 2005..These new approaches have the potential to spearhead a new era of successful adoptive immunotherapy for cancer and infectious diseases... - Importance and timing of end-of-life care discussions among gynecologic oncology patientsTeresa P Diaz-Montes
The Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
Am J Hosp Palliat Care 30:59-67. 2013..To assess the importance and desired timing of end-of-life care (EOLC) discussions among women with gynecologic cancer... - Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinomaYu Chi Chen
Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
Biochim Biophys Acta 1730:96-102. 2005..001). In conclusion, these findings represent the first characterization of human membralin and suggest that membralin is a novel tumor-associated marker in ovarian serous carcinomas... - Volume-Based Care among Young Women Diagnosed with Uterine CancerTeresa P Diaz-Montes
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, 600 North Wolfe Street, Phipps 281, Baltimore, MD 21287, USA
ISRN Surg 2011:541461. 2011..00). Women ≤50 years managed at high-volume centers had higher adjusted cost of hospital-related care (P = 0.01). Conclusion. Primary surgical care of young women with uterine cancer is often performed by low-volume providers... - Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapyRobert L Giuntoli
Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Gynecol Oncol 89:460-9. 2003..Additionally, adjuvant therapy does not appear to significantly affect survival. Finally, our highly predictive LMS risk-assessment index may be useful for counseling patients... - Ovarian preservation in stage I low-grade endometrial stromal sarcomasAndrew J Li
Department of Obstetrics Gynecology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
Obstet Gynecol 106:1304-8. 2005..To examine the impact of ovarian preservation in a case-control study of women with stage I low-grade endometrial stromal sarcomas... - A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancerKathleen N Moore
University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd WP 2470, Oklahoma City, OK 73014, and Washington University Barnes Jewish Christian Hospitals, St Louis, MO, USA
Gynecol Oncol 105:299-303. 2007..The objective of this study was to compare response rate and survival in patients with cervical cancer treated with PT or CT... - Frequent loss of pRb2/p130 in human ovarian carcinomaGiuseppina D'Andrilli
Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA
Clin Cancer Res 10:3098-103. 2004..2, a region in which deletions have been found in several human neoplasms including breast, prostatic, and ovarian carcinoma. We sought to evaluate pRb2/p130 protein expression and function in ovarian carcinoma... - TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer riskBobbie S Gostout
Section of Gynecologic Surgery, Mayo Clinic, Rochester, MN 55905, USA
Gynecol Oncol 88:326-32. 2003..We evaluated immune response genes in the HLA region of chromosome 6 to see if individual or interactive associations with cervical cancer risk could be identified... - Frozen section evaluation of cervical cold knife cone specimens is accurate in the diagnosis of microinvasive squamous cell carcinomaRobert L Giuntoli
Division of Gynecologic Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Gynecol Oncol 91:280-4. 2003..At our institution which relies heavily on intraoperative pathologic evaluation, utilizing frozen section diagnosis as the basis for definitive surgical approach did not negatively impact disease-free survival...